Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 15/20 | 1.00 |
| ▸ | MMP14 | P50281 | 14/20 | 1.00 |
| ▸ | MMP13 | P45452 | 12/20 | 1.00 |
| ▸ | MMP1 | P03956 | 12/20 | 0.81 |
| ▸ | MMP3 | P08254 | 12/20 | 0.81 |
| ▸ | MMP8 | P22894 | 11/20 | 0.81 |
| ▸ | MMP2 | P08253 | 5/20 | 0.81 |
| ▸ | MMP7 | P09237 | 2/20 | 0.77 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.74 |
| ▸ | MMP10 | P09238 | 2/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6687124 | 0.89 | MMP14 (1.00) | MMP9MMP14MMP13MMP1MMP3 | |
| SCHEMBL5919470 | 0.87 | MMP14 (1.00) | MMP9MMP14MMP13MMP1MMP3 | |
| SCHEMBL16089519 | 0.86 | MMP13 (0.81) | MMP9MMP14MMP13MMP1MMP3 | |
| SCHEMBL5919298 | 0.86 | MMP13 (0.81) | MMP9MMP14MMP13MMP1MMP3 | |
| SCHEMBL15120517 | 0.86 | MMP9 (0.93) | MMP9MMP14MMP13MMP1MMP3 | |
| SCHEMBL5919245 | 0.86 | MMP14 (1.00) | MMP9MMP14MMP13MMP1MMP3 | |
| Hydrochloric Acid SCHEMBL6461484 | 0.86 | MMP14 (0.98) | MMP9MMP14MMP13MMP1MMP3 | |
| SCHEMBL6687918 | 0.86 | MMP14 (0.94) | MMP9MMP14MMP13MMP1MMP3 | |
| Hydrochloric Acid SCHEMBL6049826 | 0.85 | MMP14 (0.98) | MMP9MMP14MMP13MMP1MMP3 | |
| SCHEMBL6684445 | 0.85 | MMP14 (0.96) | MMP9MMP14MMP13MMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150004097-A1 | MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS | IKARIA THERAPEUTICS LLC | 2015-01-01 | — | — | US | disclosed |
| US-8871189-B2 | MMP-targeted therapeutic and/or diagnostic nanocarriers | MALLINCKRODT LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140271465-A1 | MATRIX METALLOPROTEASE (MMP) TARGETED AGENTS FOR IMAGING AND THERAPY | MALLINCKRODT LLC (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140271465-A1 | MATRIX METALLOPROTEASE (MMP) TARGETED AGENTS FOR IMAGING AND THERAPY | MMP3, MMP26, MMP10 | MMP9 10/4885MMP14 9/4885MMP13 17/4885 |
| US-20150004097-A1 | MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS | MMP3, MMP9, MMP17 | MMP9 2/4885MMP14 16/4885MMP13 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.